{"id":200412,"date":"2026-08-13T11:04:22","date_gmt":"2026-08-13T05:34:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=200412"},"modified":"2026-08-13T11:04:25","modified_gmt":"2026-08-13T05:34:25","slug":"caplin-point-laboratories-vs-wockhardt","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/caplin-point-laboratories-vs-wockhardt\/","title":{"rendered":"Caplin Point Laboratories vs Wockhardt: Share Price, PE and ROE Compared"},"content":{"rendered":"
<\/div>\n

Caplin Point MCap Rs 19,947 Cr, PE 30.70x, ROE 17.88%, zero debt. Wockhardt MCap Rs 30,984 Cr, PE 74.84x, ROE 5.75%.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Caplin Point and Wockhardt are a contrasting pharma pair. Caplin at Rs 19,947 Cr runs a zero-debt operation with ROE 17.88% and trades at PE 30.70x. Wockhardt at Rs 30,984 Cr trades at a premium PE of 74.84x with ROE of only 5.75%, reflecting its novel antibiotic pipeline expectations. Caplin serves emerging markets; Wockhardt is focused on complex generics and novel molecules.<\/p>\n<\/div>\n

The Caplin Point Laboratories vs Wockhardt question comes up often among investors who follow the Pharmaceuticals space in India. Caplin Point MCap Rs 19,947 Cr, PE 30. 70x, ROE 17. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Caplin Point Laboratories vs Wockhardt as a research exercise.<\/p>\n

All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n